DUSA Pharmaceuticals, Inc., a subsidiary of Sun Pharmaceutical Industries, Inc. has agreed to pay the United States $20.75 million to resolve allegations that DUSA caused physicians to submit false claims to Medicare and the Federal Employee Health Benefit Program by knowingly promoting an administration process for the drug Levulan Kerastick that contradicted product instructions approved by the FDA and was unsupported by sufficient clinical evidence. As part of the settlement, DUSA has agreed to enter into a Corporate Integrity Agreement with HHS-OIG. The settlement resolves a lawsuit filed under the whistleblower provision of the FCA.